latest news releases from the newsroom
SYSTRAN: Revenue for Q1 2002
PARIS, April 23, 2002 (PRIMEZONE) -- SYSTRAN (Paris Stock Exchange:SYTN) (Code Euroclear Paris: 7729) today announced consolidated revenue for the first quarter as at 31 March 2002. Despite a substantial increase in sales of translation solutions targeted to the Corporate market, which is SYSTRAN's core business, the Company reported a decrease in global revenue for the first quarter, as compared with the same reporting period in 2001. Due to a lengthy pre-sales process associated with Corporate sales and to the anticipated product upgrade releases, many projected sales are currently pending.
Invitrogen, International Rectifier, Pactiv, And Information Holdings Events to be Broadcast by Vcall over the Internet
RICHMOND, Va., April 23, 2002 (PRIMEZONE) -- Invitrogen Corporation (Nasdaq:IVGN), International Rectifier Corporation (NYSE:IRF), Pactiv Corporation (NYSE:PTV), and Information Holdings, Inc. (NYSE:IHI) will broadcast their investor communication events over the Internet, Vcall, a Service of WILink announced today.
Key Technology, Power Integrations, Microsemi, and Dollar Tree Stores Events to be Broadcast by Vcall over the Internet
Richmond, Va., April 23, 2002 (PRIMEZONE) -- Key Technology, Inc. (Nasdaq:KTEC), Power Integrations, Inc. (Nasdaq:POWI), Microsemi Corporation (Nasdaq:MSCC), and Dollar Tree Stores, Inc. (Nasdaq:DLTR) will broadcast their investor communication events over the Internet, Vcall, a Service of WILink announced today.
Class Action Brought Against Johnson & Johnson for Defective Glucose Monitors -- JNJ
TORONTO, April 23, 2002 (PRIMEZONE) -- A class action has commenced against Johnson & Johnson (NYSE:JNJ) claiming that the company and its subsidiaries, Lifescan Inc. and Lifescan Canada, manufactured defective glucose monitors used by people with diabetes, under the name SureStep. The claim alleges that the defective monitors displayed inaccurate blood glucose readings, failing to indicate dangerously high blood glucose levels. The claim alleges that users experienced severe adverse reactions, which in some cases resulted in death. Consumers are seeking general damages in the amount of $500 million, plus punitive damages and other relief.